Ken Griffin Regeneron Pharmaceuticals, Inc. Put Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$1024.09 - $1201.76 $59.6 Million - $69.9 Million	58,200 Added 40.78%	200,900 $211 Million
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $60.7 Million - $73.6 Million	-68,700 Reduced 32.5%	142,700 $150 Million
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $73.6 Million - $81 Million	-81,500 Reduced 27.83%	211,400 $203 Million
Q4 2023 Feb 14, 2024	BUY	$775.18 - $881.7 $14 Million - $15.9 Million	18,000 Added 6.55%	292,900 $257 Million
Q3 2023 Nov 14, 2023	BUY	$692.45 - $844.37 $9.35 Million - $11.4 Million	13,500 Added 5.16%	274,900 $226 Million
Q2 2023 Aug 14, 2023	SELL	$700.03 - $830.35 $147 Million - $174 Million	-210,000 Reduced 44.55%	261,400 $188 Million
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $69.1 Million - $83.9 Million	-101,500 Reduced 17.72%	471,400 $387 Million
Q4 2022 Feb 14, 2023	SELL	$705.89 - $766.39 $21.7 Million - $23.5 Million	-30,700 Reduced 5.09%	572,900 $413 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $176 Million - $222 Million	306,600 Added 103.23%	603,600 $416 Million

1,534

83.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $75.2B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.